Update on Alzheimer's Disease Therapy and Prevention Strategies
W Vallen Graham1, Alessandra Bonito-Oliva1, Thomas P Sakmar1,2
1Laboratory of Chemical Biology and Signal Transduction, The Rockefeller University, New York, NY 10065;
Abstract:
Alzheimer's disease (AD) is the primary cause of age-related dementia. Effective strategies to prevent and treat AD remain elusive despite major efforts to understand its basic biology and clinical pathophysiology. Significant investments in therapeutic drug discovery programs over the past two decades have yielded some important insights but no blockbuster drugs to alter the course of disease. Because significant memory loss and cognitive decline are associated with neuron death and loss of gray matter, especially in the frontal cortex and hippocampus, some focus in drug development has shifted to early prevention of cellular pathology. Although clinical trial design is challenging, due in part to a lack of robust biomarkers with predictive value, some optimism has come from the identification and study of inherited forms of early-onset AD and genetic risk factors that provide insights about molecular pathophysiology and potential drug targets. In addition, better understanding of the Aβ amyloid pathway and the tau pathway-leading to amyloid plaques and neurofibrillary tangles, respectively, which are histopathological hallmarks of AD-continues to drive significant drug research and development programs. The main focus of this review is to summarize the most recent basic biology, biochemistry, and pharmacology that serve as a foundation for more than 50 active advanced-phase clinical trials for AD prevention and therapy.
Insights
Alzheimer's disease (AD) treatments are limited, but research into its biology and genetics offers hope. Current drug development focuses on early cellular pathology and key pathways, with over 50 clinical trials underway.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Alzheimer's disease (AD) is the leading cause of dementia, with current treatments offering limited efficacy.
- Despite extensive research, effective prevention and treatment strategies for AD remain elusive.
- Neuronal loss and gray matter reduction in key brain regions are hallmarks of AD's cognitive decline.
Purpose of the Study:
- To review recent advancements in basic biology, biochemistry, and pharmacology relevant to Alzheimer's disease.
- To provide a foundation for understanding ongoing drug discovery and clinical trial efforts for AD.
- To highlight the significance of inherited AD forms and genetic risk factors in identifying therapeutic targets.
Main Methods:
- Review of current scientific literature on Alzheimer's disease.
- Analysis of molecular pathophysiology, including amyloid and tau pathways.
- Summary of findings from advanced-phase clinical trials for AD prevention and therapy.
Main Results:
- Significant insights into AD biology and pathophysiology have been gained, though no "blockbuster" drugs have emerged.
- Focus is shifting towards early prevention of cellular pathology and identifying drug targets from genetic studies.
- Over 50 advanced-phase clinical trials are actively investigating new AD therapies.
Conclusions:
- Understanding AD's genetic underpinnings and molecular pathways is crucial for developing effective treatments.
- Early intervention targeting cellular pathology and leveraging genetic insights holds promise for future AD therapies.
- Continued research and clinical trials are essential to combat Alzheimer's disease effectively.
More Related Videos
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:30Dementia
The progression of dementia is generally gradual....
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:28Drug Therapy
Antianxiety Medications
01:15Parkinson's Disease: Overview